Optimizing Glycemic Control While Mitigating Hypoglycemic Risk in T2D - Pablo F. Mora, MD, FACE, CDE

Optimizing Glycemic Control While Mitigating Hypoglycemic Risk in T2D - Pablo F. Mora, MD, FACE, CDE

Why, When, and in Whom Do ADA/EASD Guidelines Recommend “Physiologic” Basal Insulin for T2D? Expert- and Trial-Based Evidence for the Safety and Efficacy of Long-Acting Basal Insulin.


Published

Created by

CMEducation Resources symposium

Related Presenters

Pablo Mora, FACE, MD

Pablo Mora, FACE, MD

Dallas Diabetes Research Center at Medical City Dallas (Texas)Adjunct Associate Professor University of Texas Southwestern Medical Center at Dallas (Texas)